Psoriasis and Risk of Incident Cancer: An Inception Cohort Study with a Nested Case–Control Analysis  by Brauchli, Yolanda B. et al.
Psoriasis and Risk of Incident Cancer: An Inception
Cohort Study with a Nested Case–Control Analysis
Yolanda B. Brauchli1, Susan S. Jick2, Montserrat Miret3 and Christoph R. Meier1,2
Psoriasis has been associated with lymphohematopoietic and solid cancers; however, reports have been
inconsistent. Cancer incidence was compared between psoriasis and psoriasis-free patients, and the roles of
psoriasis duration and treatment were explored in this observational study using the UK General Practice
Research Database. Among 67,761 patients, 1,703 patients had incident cancer; of whom 54% had a history of
psoriasis. Incidence rate ratios for lymphohematopoietic and pancreatic cancers were 1.81 (95% confidence
interval (CI) 1.35–2.42) and 2.20 (95% CI 1.18–4.09), respectively. In a nested case–control analysis, adjusted odds
ratios (ORs) for cancer overall were 1.50 (95% CI 1.30–1.74) for psoriasis of X4 years duration and 1.53 (95% CI
0.97–2.43) for patients receiving systemic treatment (marker of disease severity). Lymphohematopoietic
malignancy risk was highest in patients with systemic treatment. The OR for patients without systemic
treatment was 1.59 (95% CI 1.01–2.50) for psoriasis of o2 years and 2.12 (95% CI 1.45–3.10) for that of X2 years
duration. Risks of bladder/kidney and colorectal cancers were increased with longer-duration psoriasis.
Psoriasis patients may have an increased overall risk of incident cancer (mainly lymphohematopoietic and
pancreatic). Longer-term psoriasis and more severe disease may increase the risk of some cancers. These
observations need further confirmation, particularly because of the potential of findings by chance in
observational studies with subgroup analyses.
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INTRODUCTION
Psoriasis is a chronic, inflammatory disease with an estimated
prevalence of 1 to 3% in the general population (Stern et al.,
2004; Gelfand et al., 2005a, b); its impact on the quality of
life is considerable (Langley et al., 2005). The disease is
characterized by T-cell-mediated hyperproliferation of kera-
tinocytes and inflammatory processes based on a complex
genetic background. T cells and various other immune cells
infiltrate the skin and activate each other and keratinocytes
through cytokines, which appear to play a central role in the
pathogenesis of psoriasis. This process leads to an increased
proliferation of keratinocytes, as well as to the production of
other cytokines and growth factors, thereby sustaining the
inflammatory process (Sabat et al., 2007).
A derailed immune response is believed to be involved in
the pathogenesis of psoriasis-associated comorbidities. Psor-
iasis has classically been associated with high physical and
psychological morbidity. A better understanding of the
underlying immunopathogenesis and intensified epidemiolo-
gical research suggests that psoriasis is linked to additional
comorbid conditions, such as psoriatic arthritis, Crohn’s
disease, atherosclerosis, myocardial infarction, and metabolic
syndrome (Gulliver, 2008). The incidence of some cancers, in
particular lymphoma, has been reported to be increased in
patients with psoriasis. This is, in part, because of the use of
immune-suppressive and potentially carcinogenic treatments,
such as ciclosporin, methotrexate, and psoralen and ultravio-
let A (PUVA) therapy (Kimball et al., 2008).
Many published studies on the prevalence of cancer in
patients with psoriasis have been hospital based or conducted
in patients undergoing PUVA treatment, and results have
been inconsistent or difficult to interpret (Stern and Lange,
1988; Lindelof et al., 1990; Olsen et al., 1992; Bhate et al.,
1993; Stern and Vakeva, 1997; Frentz and Olsen, 1999;
Hannuksela-Svahn et al., 1999, 2000; Boffetta et al., 2001).
Among the population-based studies reported to date, two
studies conducted using the General Practice Research
Database (GPRD) focused on the risk of lymphoma (Gelfand
et al., 2003, 2006) and one, using an American claims records
database (Margolis et al., 2001), evaluated the risk of all cancers
combined, but did not stratify the results by type of cancer.
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The aim of this population-based, observational study was
to further elucidate the association between psoriasis and the
risk of developing cancer, and to provide baseline incidence
rates (IRs) of different types of cancer in patients followed up
for a maximum of 11 years after the diagnosis of psoriasis.
The effect of disease duration and treatment received was
also evaluated.
RESULTS
The study population consisted of 73,404 patients, including
36,702 with psoriasis (16,969 (46.2%) men and 19,733
(53.8%) women) and 36,702 matched psoriasis-free patients.
Approximately 55% of the patients were below the age of 50
years at the time of psoriasis diagnosis. Compared with those
in the comparison group, psoriasis patients were more likely
to be current smokers (23.9 vs 18.8% for psoriasis and
nonpsoriasis patients, respectively) and overweight (body
mass index (BMI) 25–29.9 kg m–2 in 22.7 vs 21.6% and BMI
X30 kg m–2 in 13.3 vs 10.6%, respectively). The average
follow-up time was 4.6 years.
Incidence rates of cancer in the person-time analysis
After excluding patients with a history of cancer or HIV, the
remaining study population consisted of 67,761 patients,
including 33,760 with psoriasis (46.9% men and 53.1%
women) and 34,001 psoriasis-free patients (46.8% men and
53.2% women). Within this population, we identified 1,703
patients with an incident cancer diagnosis. The IR was 5.83
(95% confidence interval (CI) 5.47–6.22) per 1,000 person-
years in patients with psoriasis, and 5.18 (95% CI 4.83–5.55)
per 1,000 person-years in patients without psoriasis. Among
the 1,703 cancer cases, 927 (54%) had a history of psoriasis
and 776 (46%) did not, resulting in a crude incidence rate
ratio (IRR) of 1.13 (95% CI 1.02–1.24) for all cancers
combined. IRs and IRRs for the different cancers are shown
in Tables 1 and 2, respectively. Overall, the risk of
developing lymphohematopoietic malignancies and cancers
of the digestive tract (in particular, pancreatic cancer) was
statistically significantly increased in patients with psoriasis,
although this was not the case for other types of cancer
(Table 2). Lymphohematopoietic malignancies included
leukemia (including other myeloproliferative disorders) and
lymphoma. All eight patients with cutaneous T-cell lympho-
ma (CTCL) had psoriasis; therefore, the IRRs for lymphohe-
matopoietic cancers and lymphomas excluding CTCL were
also calculated.
Nested case–control analysis—overall cancer risk
We included all 1,703 incident cancer cases and 6,812
matched controls without cancer in the nested case–control
analysis; patient characteristics are summarized in Table 3.
The psoriasis patients in the nested case–control analysis
received the following treatments: emollients 36%, salicylic
acid 1.0%, calcipotriol 36%, coal tar 33%, dithranol 4.9%,
tazarotene 0.6%, topical corticosteroids 72%, methotrexate
1.6%, ciclosporin 0.2%, acitretin 0.2%, azathioprine 0.2%,
hydroxyurea 0.1%, and UV therapy 0.2%. The adjusted odds
ratio (OR) of developing cancer for patients with psoriasis
was slightly over 1, relative to patients without psoriasis; this
increased with duration of psoriasis (OR of 1.50 (95% CI
1.30–1.74) in patients with X4 years psoriasis duration),
mainly among patients X60 years of age (Table 4 and
Figure 1). A possible link with severity of psoriasis, using
treatment as a proxy, was observed: OR was 1.53 (95% CI
0.97–2.43) for all patients receiving oral treatment and 2.48
(95% CI 1.08–5.72) for male patients receiving high-intensity
oral treatment (Table 4). In total, 96 patients received oral
psoriasis treatment, 72% of whom received methotrexate. In
patients who did not receive oral treatment, the adjusted OR
was 1.31 (95% CI 1.16–1.48) for psoriasis patients with X2
years disease duration. The cancer risk also increased for
patients with longer-term psoriasis duration in sensitivity
analyses, (1) excluding all patients with a prescription for
ciclosporin or methotrexate at any time and irrespective of
indication, and (2) adjusting the main models for any use of
ciclosporin and methotrexate. In a further analysis, including
only case patients who developed cancer X6 months after
the start of follow-up (n¼1,539), an OR of 1.44 (95% CI
1.28–1.63) was observed for patients with psoriasis of X2
years duration, compared with that in the psoriasis-free
comparison group. Among those who had no benign
neoplasms before the index date (372 cases and 1072
controls), OR was 1.30 (95% CI 1.13–1.49) for patients with
psoriasis of X2 years duration, compared with the psoriasis-
free reference group.
Nested case–control analysis—stratified by type of cancer
Figure 1 shows the risks of different cancer types in patients
with psoriasis in relation to duration of psoriasis and
compared with psoriasis-free patients. The overall relative
risk of developing a lymphohematopoietic malignancy was
increased by about twofold for patients with psoriasis
compared with that in the psoriasis-free control group. The
risk was highest in patients who received oral treatment,
resulting in an OR of 10.17 (95% CI 3.24–31.94) for any
treatment and 16.79 (95% CI 3.23–87.22) for those with 42
prescriptions. An analysis restricted to patients without oral
treatment yielded adjusted ORs of 1.59 (95% CI 1.01–2.50)
for patients with psoriasis of o2 years duration and 2.12
(95% CI 1.45–3.10) for those with psoriasis of X2 years
duration. Stratification by age yielded increased overall risks
for both age groups (OR 2.77 (95% CI 1.39–5.52) for patients
aged o60 years and OR 1.84 (95% CI 1.24–2.73) for those
aged X60 years). When the risks of developing lymphoma
(excluding CTCL) or leukemia were explored separately, the
highest OR was 3.22 (95% CI 1.64–6.35) for leukemia in
patients with psoriasis ofX4 years duration. The relative risk
was increased for lymphoma in patients already with early
psoriasis (Figure 1), particularly among patientso60 years of
age (data not shown). In an analysis in which we excluded all
patients who received any oral treatment, we still found an
increased lymphoma risk overall in patients with X2 years
psoriasis duration (OR 1.67, 95% CI 1.05–2.66 and OR 1.86,
95% CI 1.10–3.14, respectively).
All eight patients with CTCL had a history of psoriasis,
compared with only 34% of the 32 controls. Excluding the
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patients with CTCL from the analysis of developing lympho-
hematopoietic malignancies in patients with psoriasis yielded
lower but still statistically significantly increased ORs overall,
as well as for the various strata, by oral treatment, by duration
in patients without oral treatment, and by age (data not
shown).
For cancers of the colon/rectum, pancreas, and bladder/
kidney, the risk increased with duration of psoriasis (see test
for trend in Figure 1). Furthermore, an analysis restricted to
patients with a normal BMI yielded an OR of 6.10 (95% CI
1.27–29.32) for pancreatic cancer in psoriasis patients,
compared with that in psoriasis-free patients. The relative
risk of melanoma tended to decrease in patients with
psoriasis of longer duration (Figure 1). A tendency toward
an increased risk of brain cancer was observed in male
patients with a psoriasis duration ofX2 years (OR 3.38; 95%
CI 0.92–12.45), although the number of cases of brain cancer
was low overall (data not shown).
DISCUSSION
The findings of this large population-based study suggest that
patients with psoriasis seem to be at an increased risk of
developing certain cancers, especially patients with long
psoriasis duration and possibly severe disease. Findings to
date have been inconsistent, however, and, with the
exception of evidence that is strongly suggestive of an
increased incidence of lymphoma in this population (Gelfand
et al., 2003, 2006), no clear links between specific cancers
and psoriasis have been identified. Some studies in which the
overall cancer risk was not stratified by duration or severity of
psoriasis reported an increased risk (Olsen et al., 1992; Frentz
and Olsen, 1999; Hannuksela-Svahn et al., 2000; Boffetta
et al., 2001), but not all (Lindelof et al., 1990; Bhate et al.,
1993; Gelfand et al., 2003). The findings of the present
population-based study, based on a follow-up of a large
group of patients, provide evidence of an association
between psoriasis and specific cancers, which increases with
disease duration.
There is a suggestion in our data that the overall risk of
developing cancer (excluding nonmelanoma skin cancers) is
slightly increased in patients with psoriasis compared with
that in psoriasis-free patients. Furthermore, patients with
long-duration psoriasis seemed to be at an increased risk for
colorectal, bladder, and kidney cancers, as well as for
pancreatic and lymphohematopoietic cancers. Patients re-
ceiving oral treatment, which can be considered as a proxy
Table 1. Cancer incidence rates stratified by cancer type in patients with or without psoriasis
Non-psoriasis Psoriasis
Cases IR/1,000 py1 95% CI Cases IR/1,000 py1 95% CI
All cancer 776 5.18 4.83–5.55 927 5.83 5.47–6.22
Lymphohematopoietic malignancies 62 0.41 0.32–0.53 119 0.75 0.63–0.90
Lymphohematopoietic malignancies (excluding CTCL) 62 0.41 0.32–0.53 111 0.70 0.58–0.84
CTCL 0 NA NA 8 0.05 0.03–0.10
Lymphoma overall 36 0.24 0.17–0.33 67 0.42 0.33–0.54
Lymphoma (excluding CTCL) 36 0.24 0.17–0.33 59 0.37 0.29–0.48
Leukemia/MD 26 0.17 0.12–0.25 52 0.33 0.25–0.43
Lung 101 0.67 0.55–0.82 85 0.53 0.43–0.66
Melanoma 33 0.22 0.16–0.31 29 0.18 0.13–0.26
Breast 139 1.71 1.45–2.02 153 1.79 1.53–2.10
Prostate 95 1.38 1.13–1.69 85 1.16 0.93–1.43
Digestive organs 107 0.71 0.59–0.86 159 1.00 0.86–1.17
Pancreas 12 0.08 0.05–0.14 28 0.18 0.12–0.25
Esophagus 16 0.11 0.07–0.17 23 0.14 0.10–0.22
Colorectal 55 0.37 0.28–0.48 79 0.50 0.40–0.62
Others 24 0.16 0.11–0.24 29 0.18 0.13–0.26
Female genital organs 35 0.43 0.31–0.60 51 0.60 0.45–0.79
Bladder/kidney 43 0.29 0.21–0.39 57 0.36 0.28–0.46
Brain 16 0.11 0.07–0.17 22 0.14 0.09–0.21
Other cancers2 97 0.65 0.53–0.79 126 0.79 0.67–0.94
Metastasis 48 0.32 0.24–0.42 41 0.26 0.19–0.35
CI, confidence interval; CTCL, cutaneous T-cell lymphoma; IR, incidence rate; MD, other myeloproliferative disorders; NA, not applicable; py, person-years.
1Person times in non-psoriasis patients: overall, 149,900.2 py; men, 68,843.7 py; women, 81,056.6 py;o60 years, 104,108.4 py;X60 years, 45,791.9 py. In
psoriasis patients: overall, 158,906.0 py, men 73,553.5 py; women, 85,352.5 py; o60 years, 111,945.2 py; X60 years, 46,960.8 py.
2Other cancers: oral cavity, bone, male genital organs, parathyroid carcinoma, thymoma, and unspecified.
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for disease severity, were also at an increased risk of
developing cancer, with the greatest effect observed in men
receiving high-intensity treatment.
Other studies have reported that patients with psoriasis are
at an increased risk of developing leukemia (Lindegard, 1986;
Cooper et al., 1996; Soderberg et al., 2006) and other
myeloproliferative disorders, in particular lymphoma
(Hannuksela-Svahn et al., 1999, 2000; Tavani et al., 2000;
Margolis et al., 2001; Gelfand et al., 2003, 2006; Zhang
et al., 2004; Mellemkjaer et al., 2008). In this study, the
increased risk was most prominent in male patients (as
observed by Margolis et al., 2001) and, in the case of
lymphoma, in patients with psoriasis of shorter duration. The
ORs for the various stratifications were statistically signifi-
cantly increased when all lymphomas and lymphoma
excluding CTCL were considered, but the ORs were slightly
lower for the latter. This separate analysis allowed for the
possibility of misclassification of psoriasis and CTCL.
Furthermore, lymphoma risk was also increased in patients
not receiving any oral psoriasis treatment, which suggests that
patients who may receive biologicals also have an increased
lymphoma risk. One explanation for the increase in these
cancers may be the antigen-driven proliferation of lympho-
cytes in chronic inflammation caused by psoriasis (antigenic
stimulation hypothesis) (Soderberg et al., 2006).
Earlier studies have identified associations between
psoriasis and a range of cancers, including those of the lung
(Lindegard, 1986; Olsen et al., 1992; Frentz and Olsen, 1999;
Hannuksela-Svahn et al., 2000; Boffetta et al., 2001), liver
(Boffetta et al., 2001), oropharynx (Olsen et al., 1992; Frentz
and Olsen, 1999; Hannuksela-Svahn et al., 2000; Boffetta
et al., 2001), colon (Stern and Lange, 1988; Olsen et al.,
1992; Frentz and Olsen, 1999), kidney (Lindelof et al., 1990;
Olsen et al., 1992; Hannuksela-Svahn et al., 1999; Boffetta
et al., 2001), breast (Stern and Lange, 1988; Lindelof et al.,
1990; Stern and Vakeva, 1997; Boffetta et al., 2001), central
nervous system (Stern and Lange, 1988; Stern and Vakeva,
1997), pancreas (Boffetta et al., 2001), genital organs (Boffetta
et al., 2001), and thyroid (Stern and Vakeva, 1997). The
results of the various studies were conflicting, possibly
because of differences in study designs. With the exception
of pancreatic and lymphohematopoietic cancers, we did not
find an increased risk for these cancers in the overall psoriasis
population. In the case of smoking-related cancers, this may
be, at least in part, because of the fact that we adjusted for
smoking, whereas a similar adjustment was not undertaken in
earlier studies. For lung cancer, we found an increased risk
neither before nor after adjustment for smoking. Our study
population was rather young (more than half of all patients
were below the age of 50 years at the time of start of follow-
Table 2. Incidence rate ratios (IRRs) of cancer, stratified by type, sex, and age (reference group: patients without
psoriasis)
Overall Men Women o60 years X60 years
Type IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI)
All cancer 1.13 (1.02–1.24) 1.11 (0.97–1.28) 1.14 (1.00–1.30) 1.19 (0.99–1.43) 1.13 (1.02–1.27)
Lympho-hematopoietic malignancies 1.81 (1.35–2.42) 2.45 (1.67–3.59) 1.24 (0.79–1.94) 2.17 (1.25–3.78) 1.74 (1.24–2.45)
Excluding CTCL 1.69 (1.25–2.27) 2.23 (1.50–3.31) 1.21 (0.77–1.90) 1.98 (1.12–3.52) 1.64 (1.16–2.32)
Lymphoma overall 1.76 (1.19–2.58) 2.15 (1.27–3.63) 1.40 (0.79–2.48) 2.38 (1.19–4.75) 1.59 (1.00–2.53)
Lymphoma (excluding CTCL) 1.55 (1.03–2.31) 1.76 (1.01–3.08) 1.35 (0.76–2.41) 2.07 (1.00–4.28) 1.41 (0.87–2.28)
Leukemia/ MD 1.89 (1.21–2.94) 2.88 (1.65–5.05) 1.02 (0.49–2.11) 1.86 (0.74–4.69) 1.95 (1.18–3.23)
Lung 0.79 (0.60–1.06) 0.80 (0.56–1.13) 0.78 (0.48–1.29) 0.74 (0.35–1.58) 0.83 (0.61–1.13)
Melanoma 0.83 (0.50–1.36) 0.73 (0.36–1.46) 0.95 (0.46–1.94) 0.83 (0.43–1.60) 0.84 (0.39–1.80)
Breast 1.04 (0.83–1.31) NA NA 1.04 (0.83–1.31) 0.98 (0.68–1.40) 1.11 (0.82–1.49)
Prostate 0.84 (0.63–1.12) 0.84 (0.63–1.12) NA NA 0.76 (0.32–1.83) 0.88 (0.65–1.20)
Digestive organs 1.40 (1.10–1.78) 1.25 (0.91–1.71) 1.64 (1.14–2.38) 1.80 (1.00–3.25) 1.38 (1.06–1.79)
Pancreas 2.20 (1.18–4.09) 2.43 (0.97–6.13) 2.03 (0.88–4.69) NA NA 2.11 (1.12–3.99)
Esophagus 1.36 (0.72–2.54) 1.40 (0.64–3.08) 1.27 (0.44–3.61) 2.48 (0.76–8.09) 1.13 (0.54–2.36)
Colorectal 1.35 (0.97–1.90) 1.30 (0.82–2.05) 1.42 (0.86–2.36) 1.21 (0.53–2.74) 1.43 (0.99–2.07)
Others 1.14 (0.67–1.95) 0.80 (0.42–1.52) 2.85 (1.07–7.59) 2.79 (0.70–11.17) 1.02 (0.57–1.83)
Female genital organs 1.38 (0.91–2.11) NA NA 1.38 (0.91–2.11) 1.93 (1.04–3.59) 1.06 (0.60–1.90)
Bladder/ kidney 1.25 (0.84–1.85) 1.11 (0.70–1.76) 1.71 (0.81–3.59) 0.78 (0.24–2.53) 1.37 (0.90–2.08)
Brain 1.30 (0.69–2.45) 1.74 (0.72–4.18) 0.95 (0.38–2.39) 1.70 (0.66–4.41) 1.07 (0.46–2.52)
Other cancers1 1.23 (0.94–1.59) 1.14 (0.77–1.67) 1.31 (0.91–1.88) 1.06 (0.68–1.67) 1.35 (0.98–1.87)
Metastasis 0.81 (0.53–1.22) 1.25 (0.64–2.42) 0.60 (0.35–1.03) 1.49 (0.50–4.42) 0.75 (0.48–1.17)
CI, confidence interval; CTCL, cutaneous T-cell lymphoma; IRR, incidence rate ratio; MD, other myeloproliferative disorders; NA, not applicable.
1Other cancers: oral cavity, bone, male genital organs, parathyroid carcinoma, thymoma, and unspecified.
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up), and the mean follow-up was 4.6 years. This may explain
why we did not find an increased lung cancer risk in psoriasis
patients, as the lung cancer risk increases with advanced age
and with duration of smoking history. The risk of cancers of
the colon/rectum, pancreas, bladder, and kidney significantly
increased in patients with psoriasis of long duration. As
chronic inflammation influences initiation and progression of
neoplastic growth (Krishnamoorthy and Honn, 2006), it is
conceivable that the chronic inflammation sustained with
psoriasis of longer duration may play a role in the
development of cancer in patients with severe psoriasis.
Similar to psoriasis, lupus erythematodes and rheumatoid
arthritis are also chronic inflammatory diseases, and they
have also been associated with certain types of cancer
(Parikh-Patel et al., 2008; Smitten et al., 2008).
In this study, there was a tendency for an increase in risk of
cancer with increasing disease severity. Other studies have
also shown an association between the severity of psoriasis
and increased cancer. In a study conducted using the
Medicaid databases (Margolis et al., 2001), patients with
severe psoriasis had an increased cancer risk of 78%
compared with that in the reference group of hypertensive
patients. As patients with severe psoriasis may receive drugs,
such as methotrexate, ciclosporin, or PUVA therapy, all of
which have been associated with lymphoproliferative dis-
orders (Koo et al., 1992; Cliff et al., 1999; Stern, 2006; Suzuki
et al., 2007) and malignancies (particularly nonmelanoma
skin cancers) (Stern and Laird, 1994; Paquet and Pierard,
1998; Paul et al., 2003; Shear, 2006), we conducted a
number of sensitivity analyses in which patients with these
treatments were excluded. A longer-term history of psoriasis
(X2 years) remained associated with an increased relative
cancer risk in this subset of patients, indicating that this effect
was independent of the treatment received.
Our study has several limitations. First, in large observa-
tional studies, a certain degree of diagnosis misclassification
cannot be ruled out. However, in earlier GPRD-based studies
on psoriasis or cancer, the validity of these diagnoses has
been high (Jick et al., 1997; Gelfand et al., 2003, 2005a, b).
The epidemiology of psoriasis in the GPRD is similar to that
in other population-based studies in the United Kingdom,
92% of patients with a psoriasis code received psoriasis
treatment, and of a random sample of GPs, about 90%
confirmed the psoriasis diagnosis after 4 years of follow-up.
Furthermore, the IR of psoriasis in our study population (not
shown) is closely similar to the rate of another study on GPRD
with validated psoriasis patients (Huerta et al., 2007). In
contrast to the United States of America, most psoriasis
patients in the United Kingdom are diagnosed and managed
in primary care and are not referred to a specialist (Huerta
et al., 2007; Menter and Griffiths, 2007). Second, the initial
recording of a psoriasis diagnosis by the general practitioner
Table 3. Characteristics of cancer cases and controls in the nested case–control analysis
Characteristics No. of cases (%) (n=1,703) No. of controls (%) (n=6,812) OR adjusted1 (95% CI)
Sex2
Male 828 (48.6) 3312 (48.6) —
Female 875 (51.4) 3500 (51.4) —
Age group2
o30 years 34 (2.0) 137 (2.0) —
30–59 years 418 (24.5) 1687 (24.8) —
X60 years 1251 (73.5) 4988 (73.2) —
Smoking
Non-smoker 726 (42.6) 3232 (47.4) Reference
Current smoker 396 (23.3) 1361 (20.0) 1.31 (1.14–1.51)
Ex-smoker 418 (24.5) 1498 (22.0) 1.26 (1.10–1.45)
Unknown 163 (9.6) 721 (10.6) 1.07 (0.85–1.35)
BMI
12–18.4 kg m2 46 (2.7) 95 (1.4) 1.71 (1.18–2.48)
18.5–24.9 kg m2 548 (32.2) 2092 (30.7) Reference
25–29.9 kg m2 496 (29.1) 2173 (31.9) 0.87 (0.76–1.00)
30–60 kg m2 313 (18.4) 1149 (16.9) 1.05 (0.89–1.23)
Unknown 300 (17.6) 1303 (19.1) 0.89 (0.75–1.07)
Benign cancer 372 (21.8) 1072 (15.7) 1.53 (1.34–1.76)
BMI, body mass index; CI, confidence interval; OR, odds ratio.
1Adjusted for all covariates listed in the table.
2Matching variable.
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(GP) is not the date of onset of the disease, but rather the
point in time when the disease was brought to medical
attention for the first time. Follow-up was started at the first
recorded psoriasis diagnosis to increase the likelihood of
beginning follow-up for all patients who are at a similar stage
of the disease. Third, the number of psoriasis patients exposed
to oral therapies was low in our study population, and
therefore information on this subgroup, which may have the
greatest disease severity, is limited. It is possible that some
patients may have received oral or injectable treatment from
a specialist, which was not recorded by the GP; such
misclassification, if indeed present, may have diluted
differences in risk caused by disease severity. Fourth,
although we tested for a large number of potential
confounding factors, we cannot exclude the possibility that
unknown confounders or biases may have affected our
results. Fifth, in observational research, we cannot exclude
the potential of findings by chance because of the various
subgroup analyses. The increased risk for certain types of
solid cancers, mainly in patients with longer-term psoriasis,
may be linked to chronic inflammation with various
cytokines that are involved in the pathogenesis of psoriasis,
but the findings need further confirmation in order to exclude
findings by chance (type-a errors).
On the other hand, this study has an important strength: it
reports the findings of a follow-up of a large population of
people with psoriasis whose medical information was
recorded before cancer diagnosis, thereby eliminating con-
cerns regarding biased reporting of date of psoriasis
diagnosis, treatments, and other potential confounders.
Table 4. Relative cancer risk stratified by age, sex, and duration and severity of psoriasis in the nested case–control
analysis
Cases (%) (n=1,703) Controls (%) (n=6,812) OR adjusted1 (95% CI)
No psoriasis 776 (45.6) 3394 (49.8) Reference
Psoriasis 927 (54.4) 3418 (50.2) 1.13 (1.02–1.26)
Short-term disease (o2 years) 334 (19.6) 1517 (22.3) 0.91 (0.79–1.05)
Female 168 (9.9) 802 (11.8) 0.84 (0.69–1.03)
Male 166 (9.7) 715 (10.5) 0.98 (0.80–1.20)
o60 years 112 (6.6) 387 (5.7) 1.29 (0.99–1.68)
X60 years 222 (13.0) 1130 (16.6) 0.79 (0.66–0.93)
Long-term disease (X2 years) 593 (34.8) 1901 (27.9) 1.31 (1.17–1.48)
Female 309 (18.1) 991 (14.5) 1.29 (1.09–1.53)
Male 284 (16.7) 910 (13.4) 1.33 (1.13–1.58)
o60 years 142 (8.3) 533 (7.8) 1.14 (0.90–1.45)
X60 years 451 (26.5) 1368 (20.1) 1.37 (1.19–1.57)
Untreated psoriasis 48 (2.8) 245 (3.6) 0.81 (0.59–1.12)
Female 24 (1.4) 139 (2.0) 0.70 (0.45–1.09)
Male 24 (1.4) 106 (1.6) 0.95 (0.60–1.51)
Topical treatment 853 (50.1) 3103 (45.6) 1.15 (1.03–1.28)
Female 440 (25.8) 1613 (23.7) 1.12 (0.97–1.30)
Male 413 (24.3) 1490 (21.9) 1.18 (1.02–1.38)
Oral treatment (+/– topical) 26 (1.5) 70 (1.0) 1.53 (0.97–2.43)
High intensity 16 (0.9) 43 (0.6) 1.56 (0.87–2.80)
Female 13 (0.8) 41 (0.6) 1.25 (0.66–2.36)
High intensity 7 (0.4) 26 (0.4) 1.06 (0.45–2.46)
Male 13 (0.8) 29 (0.4) 1.99 (1.02–3.91)
High intensity 9 (0.5) 17 (0.2) 2.48 (1.08–5.72)
o60 years 7 (0.4) 21 (0.3) 1.56 (0.64–3.82)
X60 years 19 (1.1) 49 (0.7) 1.47 (0.85–2.54)
CI, confidence interval; OR, odds ratio.
1Adjusted for body mass index, smoking, and benign cancers.
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In conclusion, this observational study conducted on a
large population-based data resource explored the associa-
tion between early psoriasis and the risk of incident cancers.
Patients with psoriasis had an increased risk of developing
lymphohematopoietic or certain types of solid cancers. The
risk of solid cancers was increased primarily in psoriasis
patients with a longer-term disease history. Further investiga-
tion into common mechanisms underlying psoriasis and the
cancers identified in this study is warranted.
MATERIALS AND METHODS
This observational study with a nested case–control analysis was
conducted to quantify the risk of various cancer types in patients
with early psoriasis and to compare results with a matched
population without psoriasis.
Data source
We used data from the GPRD, a large UK-based database
established in 1987, which includes approximately five million
patients who are actively enrolled with selected GPs. These GPs
provide data for research purposes; they have been trained to record
medical information in a standard manner and to supply it
anonymously. Patients enrolled in the GPRD are representative
of the UK population with regard to age, sex, geographical
distribution, and annual turnover rate. The information recorded
includes patient demographics and characteristics (for example, age,
sex, height, weight, and smoking status), symptoms, medical
diagnoses, referrals to consultants, hospitalizations, and all drug
prescriptions, as the doctors generate prescriptions directly using the
computer, by means of a coded drug dictionary. This database has
been the source for numerous epidemiological studies (including
those of psoriasis) published in peer-reviewed journals, and has been
described in detail (Garcia Rodriguez and Perez Gutthann, 1998;
Wood and Martinez, 2004) and validated extensively (Jick et al.,
2003).
The study protocol was approved by the Independent Scientific
Advisory Committee (ISAC) for Medicines and Healthcare products
Regulatory Agency (MHRA) database research.
Study population
We included all patients with a first-time diagnosis of psoriasis
between 1 January 1994 and 31 December 2005, along with a
comparison group of the same number of patients without psoriasis.
Patients in the control group were matched to the psoriasis patients
on the basis of calendar time (follow-up for the matched patient
started at the same date as for the psoriasis patient, that is, at the date
of psoriasis diagnosis), age (same year of birth), sex, general practice,
and years of history in the GPRD. Patients witho3 years of history in
the database before first-time psoriasis diagnosis (or the correspond-
ing date in the comparison group) were excluded. The validity of
psoriasis diagnoses in the GPRD has been documented to be high
(Gelfand et al., 2003, 2005a, b), and as a result, all patients with a
recorded psoriasis diagnosis were included in the analyses, as in
earlier GPRD-based studies on psoriasis (Brauchli et al., 2008a, b, c).
Follow-up and identification of incident cancer cases
We excluded patients if they had a history of cancer (malignant or
in situ; except nonmelanoma skin cancer) or human immunodefi-
ciency virus before psoriasis diagnosis or the corresponding date in
the comparison group, and followed up all patients until one of
the following events: a first-time diagnosis of cancer (malignant or
in situ, other than nonmelanoma skin cancer); death; end of follow-
up in the medical record; or end of the follow-up period. The date of
cancer diagnosis will be referred to as the index date hereafter. We
validated all potential patients with a recorded code for incident
cancer using both a computer-based algorithm and a manual
computer profile review. We included patients if they received
cancer treatment (chemotherapy, endocrine therapy, or radio-
therapy), were referred to a specialist, were hospitalized, underwent
surgery, and/or died within 180 days after diagnosis. We excluded
patients if they did not fulfill these criteria or if there was evidence
that the cancer may have been preexisting rather than being newly
diagnosed.
Nested case–control analysis
Each patient with cancer was matched with four control patients
chosen at random from the study population based on age (same
Test for trend
P-value: <0.0001 0.01 0.05 0.002 0.02 0.0004 0.4 0.8 0.003 0.07 0.8 0.6 0.5 0.7 0.9
*P -value <0.05
Psoriasis duration
<2 years
2 to <4 years
≥4 years
Reference: patients without psoriasis
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Figure 1. Psoriasis duration and risk of cancer by specific cancer type. Ca/Co, number of cases and controls on which the results are based; CTCL, cutaneous
T-cell lymphoma; MD, other myeloproliferative disorders. Odds ratios are adjusted for age, sex, and calendar time, by matching, and for smoking, body mass
index, presence of benign cancer (all cancers), presence of gastro-oesophageal reflux disease (digestive organ cancers), use of proton-pump inhibitors (digestive
organ cancers), presence of chronic obstructive pulmonary disease (lung cancer), and for the use of estrogens, progestagens, or oral contraceptives (breast
cancer).
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year of birth), sex, and calendar time (same index date, that is, the
date on which the patient was first diagnosed with cancer).
We compared the prevalence of diagnosed psoriasis before the
index date between patients with cancer (overall and stratified by
type) and matched controls. Psoriasis patients were classified by
duration of disease (o2 years,X2 years oro2 years, 2–o4 years, or
X4 years) and treatment (no treatment, topical treatment alone
(emollients, salicylic acid, calcipotriol, coal tar, dithranol or
tazarotene preparations, or corticosteroids), and/or oral treatment
(azathioprine, ciclosporin, methotrexate, acitretin, hydroxyurea,
mycophenolate mofetil, or UV/PUVA therapy)). Patients who
received treatment were further classified by treatment intensity,
defined as p4 or 44 prescriptions per year for topical treatment,
and p2 or 42 prescriptions per year for oral treatment.
Statistical analysis
In the follow-up analysis, we assessed person-years for all patients in
the study population from the date of first psoriasis diagnosis (or the
corresponding date in the comparison group) until a patient
developed an outcome of interest or died, or the follow-up in the
medical record ended. We assessed crude IRs of a first-time cancer
diagnosis (overall and stratified by cancer type) in patients with or
without psoriasis, stratified by age and sex; crude IRRs were
calculated with 95% CI.
In the nested case–control analysis, we carried out conditional
logistic regression analyses using SAS (version 9.1; SAS Institute,
Cary, NC) to calculate relative risk estimates as ORs with 95% CI.
These analyses were controlled for the potential confounders of age,
sex, and calendar time by matching, and were further adjusted for
smoking status (none, current, past, or unknown) and BMI (o18.5,
18.5–24.9, 25.0–29.9, X30 kg m–2, or unknown) in the multivariate
model, as well as for the presence of benign cancer diagnoses before
the index date. In addition, the analysis of digestive organ cancers
was adjusted for gastroesophageal reflux disease and use of proton-
pump inhibitors (none, 1–9, or X10 prescriptions), the analysis of
lung cancer was adjusted for chronic obstructive pulmonary disease,
and the analysis of breast cancer was adjusted for the use of
estrogens, progestagens, or oral contraceptives (none, 1–9, or X10
prescriptions). The presence of other potential confounding covari-
ates (including alcoholism) not included in the final model, because
they were not materially associated with exposure or outcome, was
also investigated. A test for trend was carried out in the conditional
regression analysis to investigate the influence of psoriasis duration
on the risk of the different types of cancer.
We did not carry out any sample size calculation because our
main focus was on a high-quality analysis by, for example, excluding
psoriasis patients with less than 3 years of active history before the
psoriasis diagnosis date, by excluding patients with a history of
cancer before psoriasis diagnosis, and by calculating cancer IRs only
in patients with a first-time psoriasis diagnosis. Hence, we took all
the information we could get within this large database.
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